Merck to Acquire Terns Pharmaceuticals in $6.7 Billion Oncology Deal

Merck is expanding its cancer treatment portfolio through the acquisition of Terns Pharmaceuticals in a transaction valued at approximately $6.7 billion. The agreement, announced on March 25, provides Terns shareholders with a cash payment of $53 per share. This price represents a 42% premium over the 90-day volume-weighted average price of Terns' stock. The acquisition is strategically timed as Merck seeks to diversify its oncology offerings to mitigate the upcoming loss of patent protection for Keytruda, one of the world's top-selling drugs. The primary driver of the deal is TERN-701, a lead drug candidate designed to treat chronic myeloid Leukemia (CML). TERN-701 is currently undergoing Phase 1/2 clinical trials and has already received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Analysts have noted the strategic value of the asset, with some suggesting the price is a bargain given the potential revenue TERN-701 could generate upon market entry. The deal has already driven Terns' share price up by more than 25% throughout March. The transaction has been approved by the boards of both companies and remains subject to regulatory approval and the tendering of shares by Terns shareholders. The companies expect the deal to close within the current quarter.